BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 16977263)

  • 1. Efficacy of short term continuous subcutaneous insulin lispro versus continuous intravenous regular insulin in poorly controlled, hospitalized, type 2 diabetic patients.
    Boullu-Sanchis S; Ortega F; Chabrier G; Busch MS; Uhl C; Pinget M; Jeandidier N
    Diabetes Metab; 2006 Sep; 32(4):350-7. PubMed ID: 16977263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of continuous subcutaneous insulin infusion and multiple daily injection regimens using insulin lispro in type 1 diabetic patients on intensified treatment: a randomized study. The Study Group for the Development of Pump Therapy in Diabetes.
    Hanaire-Broutin H; Melki V; Bessières-Lacombe S; Tauber JP
    Diabetes Care; 2000 Sep; 23(9):1232-5. PubMed ID: 10977011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of continuous subcutaneous insulin infusion with lispro on hepatic responsiveness to glucagon in type 1 diabetes.
    Launay B; Zinman B; Tildesley HD; Strack T; Chiasson JL
    Diabetes Care; 1998 Oct; 21(10):1627-31. PubMed ID: 9773721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of insulin lispro in continuous subcutaneous insulin infusion treatment. Results of a multicenter trial. German Humalog-CSII Study Group.
    Renner R; Pfützner A; Trautmann M; Harzer O; Sauter K; Landgraf R
    Diabetes Care; 1999 May; 22(5):784-8. PubMed ID: 10332682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved blood glucose variability, HbA1c insuman Infusat and less insulin requirement in IDDM patients using insulin lispro in CSII. The Swedish Multicenter Lispro Insulin Study.
    Johansson UB; Adamson UC; Lins PE; Wredling RA
    Diabetes Metab; 2000 May; 26(3):192-6. PubMed ID: 10880892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized trial comparing continuous subcutaneous insulin infusion of insulin aspart versus insulin lispro in children and adolescents with type 1 diabetes.
    Weinzimer SA; Ternand C; Howard C; Chang CT; Becker DJ; Laffel LM;
    Diabetes Care; 2008 Feb; 31(2):210-5. PubMed ID: 17989308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of human regular and lispro insulins after interruption of continuous subcutaneous insulin infusion and in the treatment of acutely decompensated IDDM.
    Attia N; Jones TW; Holcombe J; Tamborlane WV
    Diabetes Care; 1998 May; 21(5):817-21. PubMed ID: 9589247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Switch to multiple daily injections with insulin glargine and insulin lispro from continuous subcutaneous insulin infusion with insulin lispro: a randomized, open-label study using a continuous glucose monitoring system.
    Bode BW; Steed RD; Schleusener DS; Strange P
    Endocr Pract; 2005; 11(3):157-64. PubMed ID: 16239201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Counterregulatory hormone responses after long-term continuous subcutaneous insulin infusion with lispro insulin.
    Tsui EY; Chiasson JL; Tildesley H; Barnie A; Simkins S; Strack T; Zinman B
    Diabetes Care; 1998 Jan; 21(1):93-6. PubMed ID: 9538976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of blood glucose stability and HbA1C between implantable insulin pumps using U400 HOE 21PH insulin and external pumps using lispro in type 1 diabetic patients: a pilot study.
    Catargi B; Meyer L; Melki V; Renard E; Jeandidier N;
    Diabetes Metab; 2002 Apr; 28(2):133-7. PubMed ID: 11976565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of various methods of intensive insulin therapy in hospital condition assessed by hypoglycaemic episodes detected with the use of continuous glucose monitoring system.
    Mozdzan M; Ruxer J; Loba J; Siejka A; Markuszewski L
    Adv Med Sci; 2006; 51():133-6. PubMed ID: 17357293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effectiveness of selected methods of the short-term intensive insulin therapy in patients with poorly controlled type 2 diabetes mellitus].
    Ruxer J; Mozdzan M; Czupryniak L; Saryusz-Wolska M; Loba J
    Pol Arch Med Wewn; 2004 Aug; 112(2):945-52. PubMed ID: 15675270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin-dependent diabetes mellitus. Multicenter Insulin Lispro Study Group.
    Anderson JH; Brunelle RL; Keohane P; Koivisto VA; Trautmann ME; Vignati L; DiMarchi R
    Arch Intern Med; 1997 Jun; 157(11):1249-55. PubMed ID: 9183237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insulin lispro in CSII: results of a double-blind crossover study.
    Zinman B; Tildesley H; Chiasson JL; Tsui E; Strack T
    Diabetes; 1997 Mar; 46(3):440-3. PubMed ID: 9032100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of a multiple daily insulin injection regimen (basal once-daily glargine plus mealtime lispro) and continuous subcutaneous insulin infusion (lispro) in type 1 diabetes: a randomized open parallel multicenter study.
    Bolli GB; Kerr D; Thomas R; Torlone E; Sola-Gazagnes A; Vitacolonna E; Selam JL; Home PD
    Diabetes Care; 2009 Jul; 32(7):1170-6. PubMed ID: 19389820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized trial comparing continuous subcutaneous insulin infusion and conventional insulin therapy in type II diabetic patients poorly controlled with sulfonylureas.
    Jennings AM; Lewis KS; Murdoch S; Talbot JF; Bradley C; Ward JD
    Diabetes Care; 1991 Aug; 14(8):738-44. PubMed ID: 1954811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improvement of HbA1c and blood glucose stability in IDDM patients treated with lispro insulin analog in external pumps.
    Melki V; Renard E; Lassmann-Vague V; Boivin S; Guerci B; Hanaire-Broutin H; Bringer J; Belicar P; Jeandidier N; Meyer L; Blin P; Augendre-Ferrante B; Tauber JP
    Diabetes Care; 1998 Jun; 21(6):977-82. PubMed ID: 9614617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved postprandial glucose control with ultra rapid lispro versus lispro with continuous subcutaneous insulin infusion in type 1 diabetes: PRONTO-Pump-2.
    Warren M; Bode B; Cho JI; Liu R; Tobian J; Hardy T; Chigutsa F; Phillip M; Horowitz B; Ignaut D
    Diabetes Obes Metab; 2021 Jul; 23(7):1552-1561. PubMed ID: 33687783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison between a multiple daily insulin injection regimen (basal once-daily glargine plus mealtime lispro) and continuous subcutaneous insulin infusion (lispro) using continuous glucose monitoring in metabolically optimized type 1 diabetes patients: A randomized open-labelled parallel study.
    Ruiz-de-Adana MS; Dominguez-Lopez ME; Gonzalez-Molero I; Machado A; Martin V; Cardona I; de-la-Higuera M; Tapia MJ; Soriguer F; Anarte MT; Rojo-Martínez G
    Med Clin (Barc); 2016 Mar; 146(6):239-46. PubMed ID: 26656958
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of insulin lispro and buffered regular human insulin administered via continuous subcutaneous insulin infusion pump.
    Raskin P; Holcombe JH; Tamborlane WV; Malone JI; Strowig S; Ahern JA; Lavent F
    J Diabetes Complications; 2001; 15(6):295-300. PubMed ID: 11711322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.